Interleukin-7

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Interleukin-7
Accession Number
DB11997  (DB05529)
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • IL-7
  • Interleukin 7 glycosylated
  • Interleukin-7 human recombinant
  • r-hIL-7
  • Recombinant human interleukin-7
  • SH-polypeptide-42
External IDs
CYT 107 / CYT-107
Categories
UNII
418XB47Y71
CAS number
858376-81-5

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911267
RxNav
1367202
Wikipedia
Interleukin-7

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentCML / Leukemia Acute Myeloid Leukemia (AML) / Smith-Magenis Syndrome1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphopenia1
1CompletedTreatmentMalignant Melanoma of Skin / Melanoma (Skin)1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1Not Yet RecruitingSupportive CareChronic Myelogenous Leukemia, BCR-ABL1 Positive / Cord Blood Transplant Recipient / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms1
1TerminatedTreatmentMalignant Melanoma of Skin / Melanoma (Skin) / Renal Cancers1
1, 2CompletedTreatmentHepatitis C Viral Infection1
1, 2TerminatedTreatmentIdiopathic CD4+ T-Lymphocytopenia1
1, 2Unknown StatusTreatmentHepatitis B Chronic Infection1
1, 2Unknown StatusTreatmentHepatitis C Viral Infection2
1, 2WithdrawnTreatmentUmbilical Cord Blood Transplant1
2CompletedTreatmentCastration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
2CompletedTreatmentSevere Sepsis With Septic Shock1
2Not Yet RecruitingTreatmentMycobacterium Infections, Nontuberculous1
2RecruitingTreatmentAdvanced Bladder Urothelial Carcinoma / Advanced Ureter Urothelial Carcinoma / Metastatic Bladder Urothelial Carcinoma / Metastatic Renal Pelvis Urothelial Carcinoma / Metastatic Ureter Urothelial Carcinoma / Metastatic Urethral Urothelial Carcinoma / Recurrent Bladder Urothelial Carcinoma / Recurrent Renal Pelvis Urothelial Carcinoma / Recurrent Ureter Urothelial Carcinoma / Recurrent Urethral Urothelial Carcinoma / Stage III Bladder Cancer AJCC v8 / Stage III Renal Pelvis Cancer AJCC v8 / Stage III Ureter Cancer AJCC v8 / Stage III Urethral Cancer AJCC v8 / Stage IV Bladder Cancer AJCC v8 / Stage IV Renal Pelvis Cancer AJCC v8 / Stage IV Ureter Cancer AJCC v8 / Stage IV Urethral Cancer AJCC v8 / Stage IVA Bladder Cancer AJCC v8 / Stage IVB Bladder Cancer AJCC v8 / Unresectable Bladder Urothelial Carcinoma / Unresectable Renal Pelvis Urothelial Carcinoma / Unresectable Ureter Urothelial Carcinoma / Urothelial carcinoma ureter metastatic1
2RecruitingTreatmentLymphoma, B Cell / Lymphoma, B-Cell1
2RecruitingTreatmentLymphocytopenia / Novel Coronavirus Infectious Disease (COVID-19)1
2RecruitingTreatmentSevere Sepsis1
2TerminatedTreatmentBreast Cancer / Cancer, Bladder / Malignant Neoplasm of Colon1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2TerminatedTreatmentSevere Sepsis With Septic Shock1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 15:09 / Updated on March 01, 2020 21:03

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates